Kiadis Pharma to present at BioCapital Europe 2020
04 Março 2020 - 4:30AM
Kiadis Pharma to present at BioCapital Europe 2020
Amsterdam, The Netherlands, March 4, 2020 –
Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext
Amsterdam and Brussels: KDS), a clinical stage
biopharmaceutical company, today announces that Arthur Lahr, chief
executive officer, will present at BioCapital Europe 2020 in
Amsterdam on Thursday, March 12, 2020 at 12:10 CET.
Kiadis Pharma Contacts:
Kiadis
Pharma:Maryann Cimino, Manager, Corporate AffairsTel. +1
617 710 7305m.cimino@kiadis.com |
Optimum Strategic
Communications:Mary Clark, Supriya Mathur, Hollie VileTel:
+44 203 950 9144David Brilleslijper (Amsterdam)Tel: +31 610 942
514kiadis@optimumcomms.com |
About Kiadis Pharma
Founded in 1997, Kiadis Pharma is building a
fully integrated biopharmaceutical company committed to developing
innovative therapies for patients with life-threatening diseases.
With headquarters in Amsterdam, the Netherlands, and offices and
activities across the United States, Kiadis Pharma is reimagining
medicine by leveraging the natural strengths of humanity and our
collective immune system to source the best cells for life.
Kiadis Pharma is listed on the regulated market
of Euronext Amsterdam and Euronext Brussels since July 2, 2015,
under the symbol KDS. Learn more at kiadis.com.
Forward Looking Statements Certain statements,
beliefs and opinions in this press release are forward-looking,
which reflect Kiadis Pharma or, as appropriate, Kiadis Pharma
officers’ current expectations and projections about future events.
By their nature, forward-looking statements involve a number of
known and unknown risks, uncertainties and assumptions that could
cause actual results, performance, achievements or events to differ
materially from those expressed, anticipated or implied by the
forward-looking statements. These risks, uncertainties and
assumptions could adversely affect the outcome and financial
effects of the plans and events described herein. A multitude of
factors including, but not limited to, changes in demand,
regulation, competition and technology, can cause actual events,
performance, achievements or results to differ significantly from
any anticipated or implied development. Forward-looking statements
contained in this press release regarding past trends or activities
should not be taken as a representation that such trends or
activities will continue in the future. As a result, Kiadis Pharma
expressly disclaims any obligation or undertaking to release any
update or revisions to any forward-looking statements in this press
release as a result of any change in expectations or projections,
or any change in events, conditions, assumptions or circumstances
on which these forward-looking statements are based. Neither Kiadis
Pharma nor its advisers or representatives nor any of its
subsidiary undertakings or any such person’s officers or employees
guarantees that the assumptions underlying such forward-looking
statements are free from errors nor does either accept any
responsibility for the future accuracy of the forward-looking
statements contained in this press release or the actual occurrence
of the anticipated or implied developments. You should not place
undue reliance on forward-looking statements, which speak only as
of the date of this press release.